Efficacy, tolerability, and safety of the oral phosphate binder VS-505 (AP301).
Bing ZhuangLiangying GanBin LiuWeijie YuanMing ShiAi PengLihua WangXiaolan ChenTongqiang LiuShiying ZhangSong WangQing GaoBaoxing WangHuixiao ZhengChanghua LiuYuan LuoHong YeHongli LinYiwen LiQiang HeFeng ZhengPing LuoGang LongWei LuKanghui LiJunwei YangYingxue Cathy LiuZhizheng ZhangXiaolin LiWeifeng ZhangLi ZuoPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
VS-505, a novel phosphate binder, was well tolerated with a manageable safety profile, and effectively and dose-dependently reduced serum phosphorus in CKD patients with hyperphosphatemia receiving MHD. Clinical Trial registration number: NCT04551300.